Search clinical trials for: Regorafenib

Total 291 results

Yehua Shen

Not yet recruiting

HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure

HCC - Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute

Recruiting

Sintilimab Combined With Fruquintinib/Regorafenib ± Radiotherapy for Third-line Treatment of Advanced Metastatic Colorectal Cancer

Colorectal Cancer | Radiotherapy | Immunotherapy | Targeted Therapy

China
Fudan University

Recruiting

HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC

Intrahepatic Cholangiocarcinoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC

Advanced/Metastatic Colorectal Cancer

China
Bayer

Not yet recruiting

An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States

Advanced Gastrointestinal Stromal Tumor

United States
Meng Chao Hepatobiliary Hospital of Fujian Medical...

Not yet recruiting

A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

Hepatocellular Carcinoma

China
China Medical University, China
Immvira Co., Limited

Not yet recruiting

A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

Colorectal Cancer Metastatic
China Medical University, China
Beijing Bio-Targeting Therapeutics Technology Co., Ltd

Not yet recruiting

A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

Colorectal Cancer Metastatic
Istituto Oncologico Veneto IRCCS
Bayer

Not yet recruiting

Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial) (MIRAGE)

Meningioma, Malignant

Italy
Bayer

Recruiting

A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

Solid Malignant Tumors

Taiwan, Japan, Korea, Republic of, France, India, Spain
West China Hospital

Recruiting

A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer

Advanced Colorectal Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

Advanced Colorectal Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

Digestive System Cancers

China
Istituto Oncologico Veneto IRCCS
Bayer S.p.A

Recruiting

Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients (REGOMA-2)

Glioblastoma, IDH-wildtype | MGMT-Methylated Glioblastoma

Italy
Shanghai JMT-Bio Inc.

Not yet recruiting

A Study of JMT101 in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (mCRC)
M.D. Anderson Cancer Center
Bayer

Not yet recruiting

Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

Gastrointestinal Stromal Tumors

United States
First Affiliated Hospital, Sun Yat-Sen University

Not yet recruiting

TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens

Liver Metastasis Colon Cancer

China
Neonc Technologies, Inc.

Recruiting

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Gastroesophageal Junction... and other conditions

United States
Ibrahim Halil Sahin
Bayer

Not yet recruiting

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

MSI-H Colorectal Cancer

United States
China Medical University, China

Not yet recruiting

TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer

Fruquintinib | Regorafenib | Gastrointestinal Tumours | TAS 102
Peking University Cancer Hospital & Institute

Recruiting

KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

Colorectal Cancer

China
Fudan University

Recruiting

Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC

Metastatic Colorectal Cancer

China
Beijing YouAn Hospital
Beijing Gene Key Life Technology Co., Ltd.

Recruiting

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

Hepatocellular Carcinoma

China
Fudan University

Recruiting

Regorafenib Alone or in Combination With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer (SLOT)

Microsatellite Stable Metastatic Colorectal Cancer

China
Sun Yat-sen University

Recruiting

Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer (REGOTORICOX)

Colorectal Cancer | Liver Metastases | MSS

China
Peking University Cancer Hospital & Institute

Recruiting

Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC

Unresectable Hepatocellular Carcinoma | Oligometastatic Disease

China
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases

Colorectal Cancer | Liver Metastases

China
Peking University Cancer Hospital & Institute

Recruiting

The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases

Colorectal Liver Metastases

China
Gustave Roussy, Cancer Campus, Grand Paris
Bayer

Recruiting

Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma (REGO-EWING)

Bone Cancer

France
Tianjin Medical University Cancer Institute and...

Recruiting

Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer

China
Wei Zhang

Recruiting

Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)

Colorectal Cancer

China
WenBo Guo

Recruiting

Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy (ROSE)

Hepatocellular Carcinoma | Regorafenib | Transcatheter Arterial ChEmoembolization

China
Sun Yat-sen University

Recruiting

Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases (RIDER)

Colorectal Cancer Liver Metastases | Regorafenib

China
Great Novel Therapeutics Biotech & Medicals Corporation

Recruiting

Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC)

Taiwan
Fudan University

Recruiting

Hepatic Arterial Infusion Chemotherapy Combined With Sintilimab and Regorafenib as Adjuvant Therapy for Colorectal Liver Metastasis Patients With a High Risk of Recurrent: a Single-arm, Phase II Study

Colorectal Liver Metastasis

China
Tongji Hospital
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma (CCGLC-008)

Hepatocellular Carcinoma Non-resectable

China
Wan-Guang Zhang
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-001)

Hepatocellular Carcinoma Non-resectable

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy

Metastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal Carcinoma | Advanced Microsatellite Stable Colorectal Carcinoma | Advanced Colorectal Adenocarcinoma

United States
Tianjin Medical University Cancer Institute and...

Recruiting

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours

Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy

China
NYU Langone Health
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Cholesterol Lowering and Residual Risk in Diabetes, Type 1 (CHORD1)

Type 1 Diabetes

United States
Instituto do Cancer do Estado de São Paulo

Recruiting

Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma (STRAT-aHCC)

Hepatocellular Carcinoma | Liver Cancer

Brazil
Rennes University Hospital

Recruiting

Microsampling Approach for Monitoring of Kinase Inhibitor Targeted Therapies (MISTIK)

Blood Concentrations of Nine Anti-cancer Drugs : Axitinib, Olaparib, regorafénib, Cabozantinib, Niraparib, Talazoparib, Palbociclib, Abemaciclib, Tucatinib

France
Sun Yat-sen University

Recruiting

Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Zhongda Hospital
Sun Yat-sen University; Jiangsu Cancer Institute & Hospital; Zhejiang University and other collaborators

Not yet recruiting

A Real World Study of Regogfinib in HCC

Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis

Colorectal Cancer | Liver Metastasis
Sun Yat-sen University

Recruiting

Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM

Colorectal Cancer Liver Metastases

China
Centre Hospitalier Universitaire de Besancon

Recruiting

Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer (REPROGRAM-02)

Metastatic Colorectal Cancer

France
China Medical University, China
The People's Hospital of Liaoning Province; The First Affiliated Hospital of... and other collaborators

Not yet recruiting

Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients

Colorectal Neoplasms | Regorafenib | Raltitrexed | Third-line Treatment

Search clinical trials for: Regorafenib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations